[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:mantle-cell-lymphoma:mki67-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Mantle Cell Lymphoma","MKI67 Gene",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06357676","Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:02.712396Z","2026-05-05T02:43:28.817702Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[20],"Phase 2","2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06263491","Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",[20],"2026-08-26T02:17:55.355429Z","2026-05-05T02:43:27.392848Z"]